Literature DB >> 22308062

QSAR studies on a number of pyrrolidin-2-one antiarrhythmic arylpiperazinyls.

Alicja Nowaczyk, Katarzyna Kulig.   

Abstract

The activity of a number of 1-[3-(4-arylpiperazin-1-yl)propyl]pyrrolidin-2-one antiarrhythmic (AA) agents was described using the quantitative structure-activity relationship model by applying it to 33 compounds. The molecular descriptors of the AA activity were obtained by quantum chemical calculations combined with molecular modeling calculations. The resulting model explains up to 91% of the variance and it was successfully validated by four tests (LOO, LMO, external test, and Y-scrambling test). Statistical analysis shows that the AA activity of the studied compounds depends mainly on the PCR and JGI4 descriptors. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00044-010-9540-x) contains supplementary material, which is available to authorized users.

Entities:  

Year:  2011        PMID: 22308062      PMCID: PMC3265727          DOI: 10.1007/s00044-010-9540-x

Source DB:  PubMed          Journal:  Med Chem Res        ISSN: 1054-2523            Impact factor:   1.965


  28 in total

1.  G protein-coupled receptors: in silico drug discovery in 3D.

Authors:  Oren M Becker; Yael Marantz; Sharon Shacham; Boaz Inbal; Alexander Heifetz; Ori Kalid; Shay Bar-Haim; Dora Warshaviak; Merav Fichman; Silvia Noiman
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-26       Impact factor: 11.205

Review 2.  Antiarrhythmic agents: current status and perspectives.

Authors:  P Mátyus; A Varró; J G Papp; H Wamhoff; I Varga; L Virág
Journal:  Med Res Rev       Date:  1997-09       Impact factor: 12.944

3.  Synthesis, antiarrhythmic, and antihypertensive effects of novel 1-substituted pyrrolidin-2-one and pyrrolidine derivatives with adrenolytic activity.

Authors:  Barbara Malawska; Katarzyna Kulig; Barbara Filipek; Jacek Sapa; Dorota Maciag; Małgorzata Zygmunt; Lucyna Antkiewicz-Michaluk
Journal:  Eur J Med Chem       Date:  2002-03       Impact factor: 6.514

4.  QSAR study for a novel series of ortho disubstituted phenoxy analogues of alpha1-adrenoceptor antagonist WB4101.

Authors:  M Pallavicini; L Fumagalli; M Gobbi; C Bolchi; S Colleoni; B Moroni; A Pedretti; C Rusconi; G Vistoli; E Valoti
Journal:  Eur J Med Chem       Date:  2006-06-05       Impact factor: 6.514

Review 5.  Clinical implications from studies of alpha1 adrenergic receptor knockout mice.

Authors:  Taka-aki Koshimizu; Akito Tanoue; Gozoh Tsujimoto
Journal:  Biochem Pharmacol       Date:  2006-11-07       Impact factor: 5.858

Review 6.  Alpha1-adrenoceptor subtypes.

Authors:  H Zhong; K P Minneman
Journal:  Eur J Pharmacol       Date:  1999-06-30       Impact factor: 4.432

7.  QSAR study for a novel series of ortho monosubstituted phenoxy analogues of alpha1-adrenoceptor antagonist WB4101.

Authors:  Laura Fumagalli; Cristiano Bolchi; Simona Colleoni; Marco Gobbi; Barbara Moroni; Marco Pallavicini; Alessandro Pedretti; Luigi Villa; Giulio Vistoli; Ermanno Valoti
Journal:  Bioorg Med Chem       Date:  2005-04-01       Impact factor: 3.641

Review 8.  Clinical use of and future perspectives on antiarrhythmic drugs.

Authors:  Juan Carlos Estrada; Dawood Darbar
Journal:  Eur J Clin Pharmacol       Date:  2008-09-02       Impact factor: 2.953

Review 9.  Classifying antiarrhythmic actions: by facts or speculation.

Authors:  E M Vaughan Williams
Journal:  J Clin Pharmacol       Date:  1992-11       Impact factor: 3.126

10.  (Phenylpiperazinyl)cyclohexylureas: discovery of alpha1a/1d-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS).

Authors:  George Chiu; Shengjian Li; Peter J Connolly; Virginia Pulito; Jingchun Liu; Steven A Middleton
Journal:  Bioorg Med Chem Lett       Date:  2007-11-22       Impact factor: 2.823

View more
  1 in total

1.  Metabolic benefits of 1-(3-(4-(o-tolyl)piperazin-1-yl)propyl)pyrrolidin-2-one: a non-selective α-adrenoceptor antagonist.

Authors:  Magdalena Kotańska; Katarzyna Kulig; Monika Marcinkowska; Marek Bednarski; Katarzyna Malawska; Paula Zaręba
Journal:  J Endocrinol Invest       Date:  2017-11-07       Impact factor: 4.256

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.